Publications in collaboration with researchers from University Hospital of Bern (4)

2024

  1. Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials

    BJOG: An International Journal of Obstetrics and Gynaecology, Vol. 131, Núm. 9, pp. 1296-1305

2023

  1. Corrigendum to “Evaluation of the impact, treatment patterns, and patient and physician perceptions of vasomotor symptoms associated with menopause in Europe and the United States” [Maturitas 164 (October 2022) 38–45] (Maturitas (2022) 164 (38–45), (S0378512222001360), (10.1016/j.maturitas.2022.06.008))

    Maturitas

  2. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study

    The Lancet, Vol. 401, Núm. 10382, pp. 1091-1102

2022

  1. Evaluation of the impact, treatment patterns, and patient and physician perceptions of vasomotor symptoms associated with menopause in Europe and the United States

    Maturitas, Vol. 164, pp. 38-45